文献速递妇科

TFAP2B在子宫内膜癌中表达降低预示不良预后:基于TCGA数据的研究

Decreased expression of TFAP2B in endometrial cancer predicts poor prognosis: A study based on TCGA data.
PubMed 文献 · Gynecol Oncol · 2018-03-28

基于TCGA公共数据,分析TFAP2B表达与子宫内膜癌临床病理特征及预后的关系;TFAP2B低表达与高级别、晚期、浆液性组织学及远处转移相关,且与更差总生存独立相关。

要点

  • TFAP2B低表达与子宫内膜癌高级别、IV期、浆液性组织学及远处转移正相关。
  • TFAP2B低表达者总生存更差,多因素分析仍为独立预后因素(HR 4.42)。
  • GSEA提示p53/缺氧、雄激素反应及Notch信号通路在TFAP2B高表达表型中差异富集。

核心结论

  • TFAP2B表达可能是子宫内膜癌不良生存的潜在预后分子标志物。
  • p53/缺氧、雄激素反应和Notch信号通路可能是TFAP2B在子宫内膜癌中调控的关键通路。

研究设计与样本

  • 基于癌症基因组图谱(TCGA)公开数据的子宫内膜癌研究。
  • 采用Wilcoxon符号秩检验和逻辑回归分析临床病理特征与TFAP2B的关系。
  • 采用Cox回归和Kaplan-Meier法分析TCGA患者总生存相关的临床病理特征。
  • 使用TCGA数据集进行基因集富集分析(GSEA)。

主要发现

  • TFAP2B低表达与高级别(高、中分化 vs 低分化 OR=2.2)、分期(I期 vs IV期 OR=2.5)、组织学(浆液性 vs 子宫内膜样 OR=1.8)、远处转移(阳性 vs 阴性 OR=2.4)显著相关,所有p值<0.05。
  • Kaplan-Meier生存分析显示TFAP2B低表达子宫内膜癌预后差于TFAP2B高表达者(p=0.013)。
  • 单因素分析显示TFAP2B低表达与较差总生存显著相关(HR 2.35;95%CI 1.17-4.73;p=0.016)。
  • 多因素分析显示TFAP2B仍与总生存独立相关(HR 4.42;95%CI 1.25-12.64;p=0.021)。
  • GSEA显示p53/缺氧通路、雄激素反应、Notch信号、脂肪酸代谢、糖酵解及雌激素反应晚期在TFAP2B高表达表型中差异富集。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transcription factor activator protein-2β (TFAP-2β) was previously reported to constituted promoter activity in endometrial carcinoma (EC). We evaluated the role of TFAP2B in ECs using publicly available data from The Cancer Genome Atlas (TCGA). METHODS: The relationship between clinical pathologic features and TFAP2B were analyzed with the Wilcoxon signed-rank test and logistic regression. Clinicopathologic characteristics associated with overall survival in TCGA patients using Cox regression and the Kaplan-Meier method. Gene Set Enrichment Analysis (GSEA) was performed using TCGA data set. RESULTS: Reduced TFAP2B expression in EC was significantly associated with high grade (OR=2.2 for well, moderate vs. poor), stage (OR=2.5 for I vs. IV), histology (OR=1.8 for serous vs. endometrioid), distant metastasis (OR=2.4 for positive vs. negative) (all p-values<0.05). Kaplan-Meier survival analysis showed that EC with TFAP2B-low had a worse prognosis than that with TFAP2B-high (p=0.013). The univariate analysis revealed that TFAP2B-low correlated significantly with a poor overall survival (OS) (HR: 2.35; 95% confidence interval [CI]: 1.17-4.73; p=0.016). The multivariate analysis revealed that TFAP2B remained independently associated with overall survival, with a HR of 4.42 (CI: 1.25-12.64; p=0.021). GSEA show that p53/hypoxia pathway, androgen response, notch signaling, fatty acid metabolism, glycolysis and estrogen response late are differentially enriched in TFAP2B high expression phenotype. CONCLUSIONS: TFAP2B expression may be a potential prognostic molecular marker of poor survival in endometrial cancer, Moreover, the p53/hypoxia, androgen response and notch signaling pathway may be the key pathway regulated by TFAP2B in EC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Wu H, Zhang J. Decreased expression of TFAP2B in endometrial cancer predicts poor prognosis: A study based on TCGA data. Gynecol Oncol. 2018. PMID: 29602546. doi:10.1016/j.ygyno.2018.03.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。